{"id":"NCT01673919","sponsor":"Hoffmann-La Roche","briefTitle":"A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study","officialTitle":"Long-term, Interventional, Open Label Extension Study Evaluating the Safety of Tocilizumab Treatment in Patients With Polyarticular-course Juvenile Idiopathic Arthritis From France Who Completed the Global, Multinational Trial (WA19977)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-02","primaryCompletion":"2014-01","completion":"2014-01","firstPosted":"2012-08-28","resultsPosted":"2016-11-02","lastUpdate":"2016-11-02"},"enrollment":7,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Juvenile Idiopathic Arthritis"],"interventions":[{"type":"DRUG","name":"tocilizumab [RoActemra/Actemra]","otherNames":[]}],"arms":[{"label":"RoActemra/Actemra","type":"EXPERIMENTAL"}],"summary":"This long-term, open-label extension study will evaluate the safety of RoActemra/Actemra (tocilizumab) in patients with polyarticular-course juvenile idiopathic arthritis who completed the WA19977 core study. Patients will continue to receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks. Anticipated time on study treatment is 104 weeks.","primaryOutcome":{"measure":"Number of Participants With Any Adverse Events and Any Serious Adverse Events","timeFrame":"Approximately 2 years","effectByArm":[{"arm":"Tocilizumab (8 mg/kg)","deltaMin":7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":9},"locations":{"siteCount":4,"countries":["France"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":7},"commonTop":["Neutropenia","Abdominal pain","Gingival bleeding","Tooth abscess","Asthma"]}}